AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01985360
Drug: Medication
RxNorm normalized name: Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
Trial: NCT03983551
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
Trial: NCT00018902
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard anti-depressant treatment with the SSRI fluoxetine
Trial: NCT01085123
Drug: Rapimelt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5.
Trial: NCT01085123
Drug: [11C]AZ10419369
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt
Trial: NCT01890135
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: randomized double blind
Trial: NCT00025623
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01820715
Drug: 600㎍ of DA-3030 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01820715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00025623
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01468636
Drug: Oral Zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg BID of oral zinc gluconate x 8 weeks
Trial: NCT01468636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg BID x 8 weeks
Trial: NCT01300455
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, orally once daily for 4 consecutive days in the evening
Trial: NCT00588913
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03700814
Drug: Co-amoxiclav
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.
Trial: NCT01260545
Drug: CA-18C3
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
Trial: NCT02538926
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02182635
Drug: Ba253BINEB
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02538926
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01479621
Drug: Placebo MDPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
Trial: NCT00215826
Drug: Alferon LDO
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01721590
Drug: Tongxinluo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongxinluo,3 capsules/time 3times/day for 1 year
Trial: NCT01721590
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules/time，3times/day for 1 year
Trial: NCT01064687
Drug: LY2189265
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01302392
Drug: Best Supportive Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).~Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle).
Trial: NCT01064687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00261703
Drug: Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2, Day 1 of the cycle + Cisplatin 75 mg/m2 Day 1 + 5-FU 750 mg/m2/day in 24-h continuous infusion for 5 days. 3 cycles will be administered, every 21 days, before the local-regional treatment (same as control group)
Trial: NCT00261703
Drug: Cisplatin, 5-fluorouracil (5-FU), radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 Day 1, 5-FU 1000 mg/m2/day in 24-h continuous infusion for 5 consecutive days. 3 cycles will be administered every 21 days, before the local-regional treatment (same as control group)
Trial: NCT01020903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, pre-op
Trial: NCT05611086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects in the control group will be given capsules containing placebo (lactose)
Trial: NCT01833819
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02450968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02966171
Drug: HMPL-453
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00569088
Drug: Chinese herbs formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).~Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days
Trial: NCT01803867
Drug: rHIgM22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via IV infusion
Trial: NCT02759991
Drug: Hecolin
RxNorm normalized name: dehydrocholic acid Oral Tablet [Decholin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.
Trial: NCT02759991
Drug: Hepa-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
Trial: NCT01329744
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection given twice per day of placebo compound, for 24 weeks
Trial: NCT02397356
Drug: Placebo first BA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised saline 1-2ml
Trial: NCT03591575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid solution that matches deferiprone oral solution in appearance and taste
Trial: NCT01313962
Drug: Flufirvitide-3 0.05 mg single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal Spray
Trial: NCT01313962
Drug: Flufirvitide-3, 0.1 mg single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray
Trial: NCT01313962
Drug: Flufirvitide-3, 0.2 mg single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal spray
Trial: NCT01313962
Drug: Flufirvitide-3, 0.4 mg single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray
Trial: NCT01345682
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly
Trial: NCT03072173
Drug: placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
Trial: NCT01686568
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00496301
Drug: Gemcitabine, Capecitabine and Sorafenib (6 cycles)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
Trial: NCT02032654
Drug: Placebo (for flucloxacillin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
Trial: NCT00156169
Drug: Dunaliella
RxNorm normalized name: DUNALIELLA SALINA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01458028
Drug: BAY85-3934
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of 20 mg BAY85-3934 as tablet
Trial: NCT01458028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
Trial: NCT02622646
Drug: Recombinant VIII factor
RxNorm normalized name: factor VIII Injection [Recombinate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a personalized pilot program with a 1 year follow up to act on the specific causes.~1. Describe PK parameters in patients on prophylaxis treatment with Advate®~2. Analyze differences in PK parameters in non-controlled vs well controlled patients~3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).~4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence).
Trial: NCT00150020
Drug: Enteric-coated mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03200613
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin 5000 units daily or Enoxaparin 40 mg subcutaneous daily
Trial: NCT01910064
Drug: GK530G
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01680003
Drug: Hepar-P
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01680003
Drug: Placebo for Hepar-P
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01110187
Drug: Fosphenytoin
RxNorm normalized name: Fosphenytoin
DrugBank: Fosphenytoin (DB01320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days
Trial: NCT02704403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01838044
Drug: Placebo and celecoxib
RxNorm normalized name: amlodipine and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment.
Trial: NCT01908595
Drug: M518101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03838484
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo skin patch will be applied to the skin.
Trial: NCT02287818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily from Day 1 to Week 12
Trial: NCT01844856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV to maintain the blind.
Trial: NCT02531165
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).
Trial: NCT03596450
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.
Trial: NCT01601210
Drug: Creatine monohydrate or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2g, 4g, and 10g of creatine monohydrate
Trial: NCT02531165
Drug: Unfractioned Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'000 IU loading dose intravenously, additional doses to achieve an ACT \>250 sec during PCI are allowed.
Trial: NCT02460224
Drug: LAG525
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAG525 was administered via intravenous (i.v.) infusion
Trial: NCT02460224
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDR001 was administered via i.v. infusion
Trial: NCT02138357
Drug: Placebo for BTDS patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo patch will be manufactured to mimic the BTDS patch.
Trial: NCT00006056
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006056
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01703793
Drug: Test Product 49778
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01703793
Drug: Test Product 10156
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01812928
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01523080
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release Gel tabs 650 mg
Trial: NCT01124981
Drug: Haemocomplettan® P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing of study medication will be individually determined based on plasma fibrinogen concentrations (measured with Clauss method during the reperfusion period on CPB) and body weight. Intravenous infusion within 10 minutes.
Trial: NCT00187070
Drug: Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description section for details of treatment interventions.
Trial: NCT00885300
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: heparin 1000iu/ml as catheter lock at the end of hemodialysis
Trial: NCT00290667
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00844792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day with meals.
Trial: NCT00290667
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02908529
Drug: Placebo, 2 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 tablets 2 hours before sleep
Trial: NCT00630929
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg oral tablet 3 times daily with meals for 6 weeks
Trial: NCT00630929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo orally for 6 weeks
Trial: NCT00630929
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg oral capsule once daily with morning meal for 6 weeks
Trial: NCT01051401
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03929835
Drug: Cannabis oil
RxNorm normalized name: Cannabis oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T1/C20 CBD
Trial: NCT03929835
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil with chlorophyl
Trial: NCT03925051
Drug: Prolia®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mAb targeting RANKL. human monoclonal antibody targeting RANKL.
Trial: NCT03925051
Drug: CMAB807
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human monoclonal antibody targeting RANKL.
Trial: NCT03330184
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02623504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage to match active treatment by mouth twice daily in the morning and in the evening.
Trial: NCT00468988
Drug: Travatan® Z
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00468988
Drug: Xalatan®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02937766
Drug: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00097812
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00068094
Drug: Probiotic-containing powder
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04497987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT00682019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00740623
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 14 weeks
Trial: NCT00491920
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 500 mg/Cholecalciferol 400 IU x2/d and placebo 2/w
Trial: NCT03689712
Drug: GC4419 90mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 minute IV infusion
Trial: NCT03689712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 minute IV infusion
Trial: NCT02510911
Drug: Caffeine (100 mg)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients after laparoscopic colectomy will receive 3 times daily capsules with 100 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement.
Trial: NCT02510911
Drug: Caffeine (200 mg)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients after laparoscopic colectomy will receive 3 times daily capsules with 200 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement.
Trial: NCT02515201
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: heparin in central venous catheter lumen
Trial: NCT04065633
Drug: Comm-Fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg PF-04965842 commercial tablet formulation under fed conditions
Trial: NCT03266172
Drug: GSK2982772 Modified Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.
Trial: NCT03266172
Drug: GSK2982772 Immediate Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.
Trial: NCT02907749
Drug: Spironolactone and carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are treated with carvedilol in combination with spironolactone.
Trial: NCT00976534
Drug: AZD1386
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg, capsules, oral, during 3 weeks
Trial: NCT00976534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, oral, during 3 weeks
Trial: NCT01203358
Drug: Exosurf
RxNorm normalized name: Exosurf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants received up to four intratracheal doses of the surfactant.